The activity of matrix metalloproteinases (MMPs) in degrading extracellular matrix is controlled by activation of pro-enzymes and inhibition of MMP tissue inhibitors (TIMPs). To assess proteolytic cascade imbalance in malignancy progression, the enzymatic activity of @entity1476 and @entity1495 and the expression and serum level of their inhibitors, @entity1552 and @entity2843 respectively, was evaluated in selected @entity1 with high-risk soft tissue @entity242 (STS). Gelatinase activity and inhibitor expression was evaluated on 69 biopsies by zymography and immunohistochemistry. @entity2843 and @entity1552 serum concentration was tested in 53 STS @entity1 and in 56 controls using a sandwich enzyme immunoassay. Clinical and biological variables were related to clinical outcome of the @entity1 . A significant gelatinolytic activity was seen in a high percentage of STS. @entity2843 expression was weak or negative in the majority of samples. The difference between disease-free (p=0.001) and overall survival (p=0.007) curves based on @entity1552 immunoreactivity was statistically significant. @entity2843 plasma concentration of 53 STS revealed significantly lower levels compared to those of 56 controls (p=0.0001). In conclusion, low levels of negative regulators of proteolysis may be related to @entity5 biological @entity146 and used to select @entity1 with poor prognosis to improve cure.

Tissue and serum loss of metalloproteinase inhibitors in high grade soft tissue XXXX .

@entity1552 :: ('7077', 'Gene') :: ['TIMP2'] @entity1 :: ('9606', 'Species') :: ['patients'] @entity242 :: ('MESH:D012509', 'Disease') :: ['sarcoma'] @entity1476 :: ('4313', 'Gene') :: ['MMP2'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity146 :: ('MESH:D001523', 'Disease') :: ['aggressiveness'] @entity2843 :: ('7076', 'Gene') :: ['TIMP', 'TIMP1'] @entity1495 :: ('4318', 'Gene') :: ['MMP9']
@entity242 :: (MESH:D012509,Disease) :: ['sarcomas']
